News

Pembrolizumab plus concurrent chemoradiotherapy demonstrated a higher progression-free survival rate than placebo plus concurrent chemoradiotherapy for patients with high-risk, locally advanced cervical cancer in the East Asia subgroup of the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study.

The combination of durvalumab, chemotherapy, and bevacizumab, followed by maintenance with olaparib, durvalumab, and bevacizumab, improved progression-free survival in newly diagnosed advanced ovarian cancer.

IL-21-engineered NK cells offer superior safety and long-term control for glioblastoma, Merck halted 2 phase 3 KEYNOTE trials of pembrolizumab, and the MonumenTAL-1 trial data is discussed.

Michael J. Mauro, MD, provides a summary of a presentation at the 2024 Society of Hematologic Oncology Annual Meeting on the recent advancements in CML treatment and applying clinical evidence to cases that are advanced.

Response outcomes with liso-cel were consistent regardless of the presence of high-risk disease features in patients with relapsed/refractory chronic lymphocytic leukemia.

While challenges exist in treating peripheral T-cell lymphoma, ongoing research is developing more effective therapies.

Updated findings from the PERSEUS study found that patients with newly diagnosed multiple myeloma benefited from a treatment regimen involving daratumumab, bortezomib, lenalidomide, and dexamethasone before and after autologous stem cell transplant.

Craig A. Portell, MD, previews his session on sequencing therapies in relapsed/refractory mantle cell lymphoma being presented at the 2024 Society of Hematologic Oncology Annual Meeting.

IBI363 has earned fast track designation from the FDA for the treatment of previously treated unresectable advanced melanoma.

Reid Merryman, MD, discusses the role of minimal residual disease in lymphoma and his presentation on the topic at the 2024 Society of Hematologic Oncology Annual Meeting.

There are remaining gaps in papillary renal cell carcinoma that data from 3 pending trials hope to fill.

Imetelstat sustained red blood cell transfusion independence in patients with lower-risk myelodysplastic syndrome, with most responders experiencing durable responses.

Partow Kebriaei, MD, discusses transplant in acute lymphoblastic leukemia.

Sonali M. Smith, MD, discusses how T-cell–directed therapies work in the context of indolent B-cell lymphoma.

The use of CAR T-cell therapy tisagenlecleucel has decreased the need for HSCT in pediatric and young adult patients with relapsed/refractory B-ALL, according to data from a noninterventional study.

Reid W. Merryman, MD, discussed the latest developments with minimal residual disease assays in the management of patients with lymphoma.

Harnessing the power of the immune system has emerged as a key approach in addressing T-cell malignancies, with efforts to leverage the immune system leading to significant improvements beyond the traditional scope of surgery, radiation therapy, and chemotherapy.

The FDA has approved FoundationOne CDx and FoundationOne Liquid CDx as companion diagnostics to be used with olaparib, abiraterone, and prednisone or prednisolone BRCA-mutated metastatic castration-resistant prostate cancer.

Fianlimab plus cemiplimab was well-tolerated and showed durable responses, in pretreated patients with advanced clear cell renal carcinoma.

Sergio A. Giralt, MD, discusses the current indications for considering stem cell transplants in patients with myelodysplastic syndrome.

Findings from the CUPISCO study found that molecularly guided therapy is more effective than standard chemotherapy for patients with unfavorable nonsquamous cancer of unknown primary.

Stefan Barta, MD, discusses the heterogeneity of T-cell lymphoma, highlighting that a one-size-fits-all approach is ineffective and emphasizing the need for tailored treatment approaches.

Advances in follicular lymphoma treatment have included the development of novel immunotherapies in relapsed and refractory disease and long-term follow-up of pivotal trials.

This designation follows the fast track designation that was granted to OBX-115 for the same indication in July 2024.

Jeff Sharman, MD, discusses the clinical implications for oncologists based on data from the ELEVATE-TN trial.

Here is a look back on all the FDA happenings from the month of August 2024.

In an interview, Jaime Merchan, MD, explained the background and data from a biomarker analysis of the CLEAR trial in advanced renal cell carcinoma.